Table 2. Synthetic peptides currently produced by the pharmaceutical industry and strategy of synthesis employed. |
Peptide |
Nr amino acid residues |
Amount |
Legal status |
Strategy of synthesis |
ACTH (1-24) |
24 |
50-100 kg |
Commercial |
SPS |
Atosiban |
9 |
50-100 kg |
Commercial |
SPS |
Cetrorelix |
10 |
10-100 kg |
Commercial |
SPS |
Eptifibatide |
7 |
>200 kg |
Commercial |
SPS |
Exendine |
39 |
|
Phase III |
SPPS |
Fuzeon-20 |
36 |
4000 kg |
Approved |
SPPS and Frag |
LH_RH |
10 |
150-200 kg |
Commercial |
SPS and SPPS |
Buserellin |
9 |
NIA |
Commercial |
SPPS |
Dislorelin |
9 |
NIA |
Commercial |
SPPS |
Coselin |
10 |
NIA |
Commercial |
SPPS |
Leuprolide |
9 |
250 kg |
Commercial |
SPPS |
Triptorelin |
10 |
NIA |
Commercial |
SPPS |
Parathyroid hormone |
34 |
NIA |
Approval |
SPPS |
Pramlintide |
37 |
>10 kg |
Phase III |
SPS and SPPS |
Salmon calcitonin |
32 |
NIA |
Commercial |
SPS and SPPS |
Somatostatin |
14 |
NIA |
Approved |
SPS and SPPS |
Lanreotide |
8 |
100-200 kg |
Approval |
SPPS |
Octreotide |
8 |
100-200 kg |
Approval |
SPS |
Theratope |
43 |
NIA |
Phase III |
SPS and Frag |
Thymalfasin |
28 |
NIA |
Approval |
SPPS |
Thymosine alpha-1 |
28 |
200-400 kg |
Approval |
SPPS |
Vassopresin analogs |
|
|
|
|
Desmopressin |
9 |
5-10 kg |
Approved |
SPS and SPPS |
Lypressin |
9 |
5-10 kg |
Approved |
SPS |
Pitressin |
9 |
5-10 kg |
Approved |
SPS |
Terlipressin |
9 |
5-10 kg |
Approved |
SPS and SPPS |
Zinconotide |
25 |
1-5 kg |
Phase III |
SPPS |
Frag: fragment
condensation in solution. |
|